INDP (Indaptus Therapeutics) Insider Ownership: 8.79 % (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INDP Indaptus Therapeutics Inc INDP
30 GF Score
Price $1.32
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics Insider Ownership?

Indaptus Therapeutics INDP +1.55% 30 Insider Ownership is 8.79 % as of Aug. 04, 2026. GuruFocus rates INDP with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Indaptus Therapeutics's insider ownership is 8.79%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Indaptus Therapeutics's Institutional Ownership is 0.06%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Indaptus Therapeutics's Float Percentage Of Total Shares Outstanding is 98.79%.

Indaptus Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Indaptus Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indaptus Therapeutics Insider Ownership Chart

Indaptus Therapeutics Historical Data

The historical data trend for Indaptus Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-06-30 2026-07-31
Insider Ownership 35.77 2.67 1.38 1.38 1.38 0.87 19.58 20.70 8.79 8.79
INDP
30GF Score
Indaptus Therapeutics Inc INDP
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.79 % mean?
Indaptus Therapeutics (INDP) has a Insider Ownership of 8.79 % as of Aug. 04, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Indaptus Therapeutics and its competitors.
Is Indaptus Therapeutics' Insider Ownership too high?
Indaptus Therapeutics' current Insider Ownership is 8.79 %. Overall, Indaptus Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' Insider Ownership compare to UPB and RCKT?
Indaptus Therapeutics' Insider Ownership of 8.79 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Indaptus Therapeutics and its competitors. Indaptus Therapeutics's current Insider Ownership is 8.79 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current Insider Ownership of 8.79 %. The current Insider Ownership is 8.79 %. Indaptus Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current Insider Ownership is 8.79 % as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
30GF Score

Get the complete analysis for INDP

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price